Cargando…
Will JAK1/2 inhibitors change the standard of care for myelofibrosis?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538792/ https://www.ncbi.nlm.nih.gov/pubmed/23319999 http://dx.doi.org/10.5045/kjh.2012.47.4.241 |
| _version_ | 1782255017900638208 |
|---|---|
| author | Jung, Chul Won |
| author_facet | Jung, Chul Won |
| author_sort | Jung, Chul Won |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3538792 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2012 |
| publisher | Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-35387922013-01-14 Will JAK1/2 inhibitors change the standard of care for myelofibrosis? Jung, Chul Won Korean J Hematol Perspective Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2012-12 2012-12-24 /pmc/articles/PMC3538792/ /pubmed/23319999 http://dx.doi.org/10.5045/kjh.2012.47.4.241 Text en © 2012 Korean Society of Hematology http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Perspective Jung, Chul Won Will JAK1/2 inhibitors change the standard of care for myelofibrosis? |
| title | Will JAK1/2 inhibitors change the standard of care for myelofibrosis? |
| title_full | Will JAK1/2 inhibitors change the standard of care for myelofibrosis? |
| title_fullStr | Will JAK1/2 inhibitors change the standard of care for myelofibrosis? |
| title_full_unstemmed | Will JAK1/2 inhibitors change the standard of care for myelofibrosis? |
| title_short | Will JAK1/2 inhibitors change the standard of care for myelofibrosis? |
| title_sort | will jak1/2 inhibitors change the standard of care for myelofibrosis? |
| topic | Perspective |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538792/ https://www.ncbi.nlm.nih.gov/pubmed/23319999 http://dx.doi.org/10.5045/kjh.2012.47.4.241 |
| work_keys_str_mv | AT jungchulwon willjak12inhibitorschangethestandardofcareformyelofibrosis |